Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	CN¥46.00	-3.85%	930,700
05/11/26	CN¥47.84	+5.61%	1,075,500
04/11/26	CN¥45.30	+2.72%	1,040,446
03/11/26	CN¥44.10	-4.30%	747,700
02/11/26	CN¥46.08	+1.16%	1,112,500

End-of-day quote Shenzhen S.E.

More quotes

End-of-day quote Shenzhen S.E. 06/11/2026			5-day change	1st Jan Change
46.00 ^CNY	-3.85%		+0.99%	-22.91%

10-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
09-29	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI

Market Cap	3.68B 551M 494M 452M 412M 777M 51.8B 801M 5.44B 2.17B 27.64B 2.07B 2.02B 87.25B	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	4.01B 600M 538M 492M 449M 846M 56.4B 872M 5.93B 2.36B 30.09B 2.25B 2.2B 95B	EV / Sales 2024	6.46x	EV / Sales 2025	32.7x
Free-Float	32.51%	Yield 2024 *	-	Yield 2025	-

10-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
09-29	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI
09-21	Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index	CI
08-26	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Duorui Pharmaceutical Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 77.3 million.	CI
08-26	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-23	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
04-23	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
04-23	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
02-27	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
02-24	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
01-21	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI

1 day	-3.85%
1 week	+0.99%
Current month	+0.99%
1 month	-27.18%
3 months	-17.41%
6 months	-43.70%
Current year	-22.91%

Tibet Duo Rui Pharmaceutical Co., Ltd. Stock

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news: Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	42.6	47.99
1 month	42.6	64
Current year	42.6	98.29
1 year	42.6	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	01/12/2018
Chao Li DFI	Director of Finance/CFO	47	01/05/2017
Fen Jin DFI	Director of Finance/CFO	46	01/12/2017

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	01/12/2017
Shao Zhong Zhang BRD	Director/Board Member	70	21/02/2020
Qin Deng BRD	Director/Board Member	58	21/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-3.85%	+0.99%	-17.72%	+58.51%	551M
ELI LILLY AND COMPANY	-0.79%	-4.48%	+44.44%	+127.49%	1,206B
JOHNSON & JOHNSON	+1.43%	+1.11%	+47.73%	+82.08%	665B
ABBVIE INC.	+1.07%	-1.21%	+32.99%	+106.31%	515B
ROCHE HOLDING AG	-0.36%	-3.25%	+47.17%	+64.58%	381B
MERCK & CO., INC.	-0.14%	-1.87%	+71.05%	+40.63%	362B
NOVARTIS AG	-0.78%	-0.52%	+30.57%	+57.98%	307B
ASTRAZENECA PLC	-0.80%	-0.21%	+8.54%	+35.56%	289B
AMGEN INC.	+0.03%	-1.20%	+45.89%	+68.76%	249B
GILEAD SCIENCES, INC.	-0.41%	-2.22%	+35.24%	+105.68%	207B
Average	-0.46%	-1.40%	+34.59%	+74.76%	418.03B
Weighted average by Cap.	-0.05%	-1.96%	+42.23%	+88.38%

	2024	2025
Net sales	241M 36.03M 32.32M 29.53M 26.96M 50.8M 3.39B 52.4M 356M 142M 1.81B 135M 132M 5.71B	154M 23.09M 20.71M 18.92M 17.27M 32.55M 2.17B 33.57M 228M 90.95M 1.16B 86.65M 84.8M 3.66B
Net income	-62.67M -9.38M -8.42M -7.69M -7.02M -13.23M -882M -13.65M -92.71M -36.97M -471M -35.22M -34.47M -1.49B	-102M -15.3M -13.72M -12.54M -11.45M -21.57M -1.44B -22.25M -151M -60.27M -767M -57.42M -56.19M -2.42B
Net Debt	135M 20.17M 18.09M 16.53M 15.09M 28.43M 1.9B 29.33M 199M 79.45M 1.01B 75.7M 74.08M 3.19B	327M 48.93M 43.88M 40.1M 36.61M 68.97M 4.6B 71.15M 483M 193M 2.45B 184M 180M 7.75B